-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pfizer recently announced that the US FDA has approved TicoVac (tick-borne encephalitis vaccine) for the prevention of tick-borne encephalitis (TBE) in individuals over 1 year old
TBE is a viral infection of the brain and spine, which can be transmitted to humans through the bite of a virus-infected tick
Pfizer’s TBE vaccine is marketed in Europe under the trade names of FSME-immune and TicoVac, and in the United States under the trade name of TicoVac, developed using a "seed" virus similar to the TBE virus found in nature
Clinical trials evaluated the safety and immunogenicity of TicoVac in two age groups (1-15 years and >16 years)
Reference materials:
[1] US FDA Approves TICOVAC™, Pfizer's Tick-Borne Encephalitis (TBE) Vaccine.